Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

Competing Interests: Disclosure AF reports personal fees as an invited speaker from LEO Pharma, Pfizer, Rovi, Sanofi, Stago and Werfen. CA reports personal fees as an invited speaker from Bayer, Bristol-Myers Squibb (BMS)/Pfizer, Daiichi Sankyo and Sanofi; and personal fees for advisory board membership from Bayer, BMS/Pfizer and Sanofi. MDN reports personal fees as an invited speaker from Bayer, Daiichi Sankyo and Viatris; personal fees for advisory board membership from LEO Pharma and Pfizer; and institutional funding from LEO Pharma. GG reports no conflicts of interest. LJP reports personal fees as an invited speaker from Actelion, Daiichi Sankyo, LEO Pharma, MSD, Pfizer and Rovi; and institutional funding from LEO Pharma and MSD. FL reports personal fees as an invited speaker from Bayer, BMS, Janssen-Cilag, LEO Pharma, Mitsubishi Tanabe Pharma and Pfizer; personal fees for advisory board membership from Alexion, Aspen, BioMarin, Chugai, CSL Behring, Daiichi Sankyo, GSK, Mylan (Viatris), Roche, SOBI, Takeda and Werfen; and institutional funding from Bayer, CSL Behring, Intersero, Novo Nordisk and SOBI. RL reports personal fees as an invited speaker from BMS, Daiichi Sankyo, Janssen, Laboratorios Rovi, LEO Pharma and Sanofi; personal fees for advisory board membership from Janssen, LEO Pharma and Sanofi; institutional funding from Laboratorios Rovi; and complimentary product samples from Laboratorios Rovi. MM reports personal fees as an invited speaker from Sun Pharma; and personal fees for advisory board membership from BMS, Merck Sharp & Dohme (MSD), Novartis, Pierre Fabre and Sanofi. AM reports personal fees as an invited speaker from Bayer, BMS, LEO Pharma, Pfizer and Sanofi; personal fees for advisory board membership from Bayer, BMS, LEO Pharma and Pfizer; and personal fees for a writing engagement from BMS and LEO Pharma. IP reports personal fees as an invited speaker from Bayer, BMS, Pfizer and Sanofi; and personal fees for advisory board membership from Bayer, BMS, Daiichi Sankyo and Pfizer. MS reports personal fees as an invited speaker for art tempi at ASCO Direct, BMS, Esanum, MSD, Pfizer and Pierre Faber; personal fees for advisory board membership from Amgen, AstraZeneca, Sanofi and Servier; expert testimony for Incyte and institutional funding as local principal investigator (PI) from Amgen, AstraZeneca, BeiGene, BMS and GSK; non-remunerated membership to Association of Scientific Medical Societies in Germany Guidelines Pancreatic and Liver Cancer; and a non-remunerated leadership role at Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V (AIO) Leitgruppe Pancreatic Cancer. KS reports personal fees for advisory board membership from Amgen and BMS; and institutional funding from MSD. AY reports personal fees as an invited speaker from LEO Pharma; and personal fees for advisory board membership from BMS/Pfizer Alliance. KJ reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda) and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm and Voluntis; royalties from Elsevier and Wolters Kluwer; institutional funding as a coordinating PI from Helsinn; non-remunerated membership to the American Society for Clinical Oncology, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie and Multinational Association of Supportive Care in Cancer; a non-remunerated leadership role at Arbeitsgemeinschaft Supportive Massnahmen in der Onkologie, AIO and ESMO; and a non-remunerated advisory role at Deutsche Krebshilfe, the Federal Ministry of Education and Research, the Hamburg Cancer Society and Leopoldina.